Clinical Trial Update: Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial on NBI-98854 in pediatric Tourette syndrome was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tourette Syndrome

Drugs mentioned

• NBI-98854

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Tourette Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2022-05-17